Herpes Labialis

5
Pipeline Programs
4
Companies
5
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
1
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 3 programs with unclassified modality

On Market (1)

Approved therapies currently available

Novartis
FAMVIRApproved
famciclovir
Novartis
oral1994

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
1 program
1
1
FamciclovirPhase 2/3Small Molecule1 trial
Active Trials
NCT00878072Completed53Est. Jun 2010
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
1
GlutaminePhase 21 trial
Active Trials
NCT00913692TerminatedEst. Dec 2011
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
1
HDIT101Phase 22 trials
Active Trials
NCT04539483Terminated761Est. May 2023
NCT04165122Completed122Est. Nov 2021
AiCuris
AiCurisGermany - Wuppertal
1 program
1
Pritelivir 5% w/w ointmentPhase 21 trial
Active Trials
NCT02871492CompletedEst. Oct 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
NovartisFamciclovir
Heidelberg PharmaHDIT101
Heidelberg PharmaHDIT101
AiCurisPritelivir 5% w/w ointment
Allergy TherapeuticsGlutamine

Clinical Trials (5)

Total enrollment: 936 patients across 5 trials

NCT00878072NovartisFamciclovir

Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis

Start: Mar 2009Est. completion: Jun 201053 patients
Phase 2/3Completed
NCT04539483Heidelberg PharmaHDIT101

Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 1 Infection

Start: Oct 2020Est. completion: May 2023761 patients
Phase 2Terminated
NCT04165122Heidelberg PharmaHDIT101

Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 2 Infection

Start: Nov 2019Est. completion: Nov 2021122 patients
Phase 2Completed
NCT02871492AiCurisPritelivir 5% w/w ointment

Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes

Start: Nov 2016Est. completion: Oct 2017
Phase 2Completed
NCT00913692Allergy TherapeuticsGlutamine

A Randomized Double-Blind Control-Comparison Crossover Trial of Oral Glutamine to Suppress Frequently Recurrent Herpes Labialis

Start: Jun 2009Est. completion: Dec 2011
Phase 2Terminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space